181 related articles for article (PubMed ID: 24389023)
1. Structural basis for potent inhibition of SIRT2 deacetylase by a macrocyclic peptide inducing dynamic structural change.
Yamagata K; Goto Y; Nishimasu H; Morimoto J; Ishitani R; Dohmae N; Takeda N; Nagai R; Komuro I; Suga H; Nureki O
Structure; 2014 Feb; 22(2):345-52. PubMed ID: 24389023
[TBL] [Abstract][Full Text] [Related]
2. Crystal structure analysis of human Sirt2 and its ADP-ribose complex.
Moniot S; Schutkowski M; Steegborn C
J Struct Biol; 2013 May; 182(2):136-43. PubMed ID: 23454361
[TBL] [Abstract][Full Text] [Related]
3. Selective Sirt2 inhibition by ligand-induced rearrangement of the active site.
Rumpf T; Schiedel M; Karaman B; Roessler C; North BJ; Lehotzky A; Oláh J; Ladwein KI; Schmidtkunz K; Gajer M; Pannek M; Steegborn C; Sinclair DA; Gerhardt S; Ovádi J; Schutkowski M; Sippl W; Einsle O; Jung M
Nat Commun; 2015 Feb; 6():6263. PubMed ID: 25672491
[TBL] [Abstract][Full Text] [Related]
4. Discovery of macrocyclic peptides armed with a mechanism-based warhead: isoform-selective inhibition of human deacetylase SIRT2.
Morimoto J; Hayashi Y; Suga H
Angew Chem Int Ed Engl; 2012 Apr; 51(14):3423-7. PubMed ID: 22374802
[TBL] [Abstract][Full Text] [Related]
5. Seeding for sirtuins: microseed matrix seeding to obtain crystals of human Sirt3 and Sirt2 suitable for soaking.
Rumpf T; Gerhardt S; Einsle O; Jung M
Acta Crystallogr F Struct Biol Commun; 2015 Dec; 71(Pt 12):1498-510. PubMed ID: 26625292
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and biological activity of a novel series of human sirtuin-2-selective inhibitors.
Suzuki T; Khan MN; Sawada H; Imai E; Itoh Y; Yamatsuta K; Tokuda N; Takeuchi J; Seko T; Nakagawa H; Miyata N
J Med Chem; 2012 Jun; 55(12):5760-73. PubMed ID: 22642300
[TBL] [Abstract][Full Text] [Related]
7. Development of 1,2,4-Oxadiazoles as Potent and Selective Inhibitors of the Human Deacetylase Sirtuin 2: Structure-Activity Relationship, X-ray Crystal Structure, and Anticancer Activity.
Moniot S; Forgione M; Lucidi A; Hailu GS; Nebbioso A; Carafa V; Baratta F; Altucci L; Giacché N; Passeri D; Pellicciari R; Mai A; Steegborn C; Rotili D
J Med Chem; 2017 Mar; 60(6):2344-2360. PubMed ID: 28240897
[TBL] [Abstract][Full Text] [Related]
8. Structure-based design of pseudopeptidic inhibitors for SIRT1 and SIRT2.
Huhtiniemi T; Salo HS; Suuronen T; Poso A; Salminen A; Leppänen J; Jarho E; Lahtela-Kakkonen M
J Med Chem; 2011 Oct; 54(19):6456-68. PubMed ID: 21895016
[TBL] [Abstract][Full Text] [Related]
9. Molecular modeling study for conformational changes of Sirtuin 2 due to substrate and inhibitor binding.
Sakkiah S; Chandrasekaran M; Lee Y; Kim S; Lee KW
J Biomol Struct Dyn; 2012; 30(3):235-54. PubMed ID: 22694102
[TBL] [Abstract][Full Text] [Related]
10. X-ray crystal structure guided discovery of new selective, substrate-mimicking sirtuin 2 inhibitors that exhibit activities against non-small cell lung cancer cells.
Yang LL; Wang HL; Zhong L; Yuan C; Liu SY; Yu ZJ; Liu S; Yan YH; Wu C; Wang Y; Wang Z; Yu Y; Chen Q; Li GB
Eur J Med Chem; 2018 Jul; 155():806-823. PubMed ID: 29957526
[TBL] [Abstract][Full Text] [Related]
11. Molecular docking and dynamics simulation, receptor-based hypothesis: application to identify novel sirtuin 2 inhibitors.
Sakkiah S; Thangapandian S; Park C; Son M; Lee KW
Chem Biol Drug Des; 2012 Aug; 80(2):315-27. PubMed ID: 22564257
[TBL] [Abstract][Full Text] [Related]
12. Molecular modelling studies of sirtuin 2 inhibitors using three-dimensional structure-activity relationship analysis and molecular dynamics simulations.
Chuang YC; Chang CH; Lin JT; Yang CN
Mol Biosyst; 2015 Mar; 11(3):723-33. PubMed ID: 25502412
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and structure-activity relationship studies of novel sirtuin 2 (SIRT2) inhibitors with a benzamide skeleton.
Sakai T; Matsumoto Y; Ishikawa M; Sugita K; Hashimoto Y; Wakai N; Kitao A; Morishita E; Toyoshima C; Hayashi T; Akiyama T
Bioorg Med Chem; 2015 Jan; 23(2):328-39. PubMed ID: 25515955
[TBL] [Abstract][Full Text] [Related]
14. Drug repurposing for ligand-induced rearrangement of Sirt2 active site-based inhibitors via molecular modeling and quantum mechanics calculations.
Bharadwaj S; Dubey A; Kamboj NK; Sahoo AK; Kang SG; Yadava U
Sci Rep; 2021 May; 11(1):10169. PubMed ID: 33986372
[TBL] [Abstract][Full Text] [Related]
15. Discovery of bicyclic pyrazoles as class III histone deacetylase SIRT1 and SIRT2 inhibitors.
Therrien E; Larouche G; Nguyen N; Rahil J; Lemieux AM; Li Z; Fournel M; Yan TP; Landry AJ; Lefebvre S; Wang JJ; MacBeth K; Heise C; Nguyen A; Besterman JM; Déziel R; Wahhab A
Bioorg Med Chem Lett; 2015 Jun; 25(12):2514-8. PubMed ID: 25971769
[TBL] [Abstract][Full Text] [Related]
16. Propofol inhibits SIRT2 deacetylase through a conformation-specific, allosteric site.
Weiser BP; Eckenhoff RG
J Biol Chem; 2015 Mar; 290(13):8559-68. PubMed ID: 25666612
[TBL] [Abstract][Full Text] [Related]
17. Identification of Diketopiperazine-Containing 2-Anilinobenzamides as Potent Sirtuin 2 (SIRT2)-Selective Inhibitors Targeting the "Selectivity Pocket", Substrate-Binding Site, and NAD
Mellini P; Itoh Y; Elboray EE; Tsumoto H; Li Y; Suzuki M; Takahashi Y; Tojo T; Kurohara T; Miyake Y; Miura Y; Kitao Y; Kotoku M; Iida T; Suzuki T
J Med Chem; 2019 Jun; 62(12):5844-5862. PubMed ID: 31144814
[TBL] [Abstract][Full Text] [Related]
18. N(epsilon)-Modified lysine containing inhibitors for SIRT1 and SIRT2.
Huhtiniemi T; Suuronen T; Lahtela-Kakkonen M; Bruijn T; Jääskeläinen S; Poso A; Salminen A; Leppänen J; Jarho E
Bioorg Med Chem; 2010 Aug; 18(15):5616-25. PubMed ID: 20630764
[TBL] [Abstract][Full Text] [Related]
19. Identification of inhibitor binding site in human sirtuin 2 using molecular docking and dynamics simulations.
Sakkiah S; Arooj M; Kumar MR; Eom SH; Lee KW
PLoS One; 2013; 8(1):e51429. PubMed ID: 23382805
[TBL] [Abstract][Full Text] [Related]
20. Constrained peptides with target-adapted cross-links as inhibitors of a pathogenic protein-protein interaction.
Glas A; Bier D; Hahne G; Rademacher C; Ottmann C; Grossmann TN
Angew Chem Int Ed Engl; 2014 Feb; 53(9):2489-93. PubMed ID: 24504455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
